Mats brings over 37 years of experience in the pharmaceutical industry, with a career marked by significant contributions in Discovery, Development, Manufacturing, IT R&D, Patents, Clinical Science, and Data Science & AI. His innovative work and leadership in these fields have placed him at the forefront of technological advancements in healthcare.

After a notable 12-year tenure as the global integration lead for Electronic Health Records (EHR) services at AstraZeneca, Mats now holds several key roles in the industry: Senior Industry Scientific Director and Co-Founder of i~HD (European Institute for Innovation through Health Data), Executive Strategic Advisor for IgniteData, which develops a system-agnostic EHR-to-EDC solution for clinical trials, Chairman of the Board of the Research Foundation IMIT (Institute of Managing Innovation & Technology), which includes Chalmers University of Technology, Royal Institute of Technology, Lund University of Technology, and Stockholm School of Business, and Board Member of the Center for Health Governance at Gothenburg University.

‍

“The innovative and advanced technology that IOMED is developing has the potential to transform healthcare, making it more efficient and accessible. By integrating cutting-edge NLP capabilities and the OMOP common data model, IOMED stands out in the industry, providing unparalleled insights and driving significant advancements in personalized medicine and clinical research. I am eager to collaborate with this dynamic and talented team to drive solutions that truly make a difference in people's lives. IOMED’s commitment to excellence and its forward-looking vision are inspiring, and I look forward to contributing my experience and knowledge to help achieve the goals defined by the European Health Data Space and contribute to building a secure and interoperable data space.” says Mats.

‍

Mats has an extensive portfolio, including over 70 publications, books, and patents in Life Science, Economics, and Social Science. His expertise encompasses Health Data Science & AI, Clinical Science, Clinical Trials Management, Business Modelling, Innovation & Creativity Management, and Device Development.

‍

“For IOMED, having Mats Sundgren on board as a Scientific Advisor is a significant milestone. His extensive experience and deep understanding of health data strategy and technological innovation will provide unparalleled guidance as we continue to develop our AI-powered healthcare data activation platform. Mats’ vision will be instrumental in driving forward our mission to revolutionize healthcare” says Rohit Mistry, CEO of IOMED.

‍